Sundaresan Swami, Nguyen Kathleen T, Nelson Kelly C, Ivan Doina, Patel Anisha B
The University of Texas Health Science Center at Houston - UT Health, Department of Dermatology, Houston, Texas,.
Dermatol Online J. 2017 Sep 15;23(9):13030/qt2513974h.
Nivolumab, a relatively novel immune checkpoint inhibitor with FDA approval in 2014, is gaining greater utilization due to its efficacy in treating metastatic melanoma. Many of the cutaneous immune-related adverse events (irAEs) being catalogued do not necessitate discontinuation of immunotherapy and are managed with supportive therapy. We present a case of erythema multiforme major secondary to nivolumab requiring hospitalization and discontinuation of treatment. This is only the second reported case of nivolumab-induced erythema multiforme in the literature we are aware of, and emphasizes the importance of oncologists working in conjunction with dermatologists for prompt diagnosis and management.
纳武单抗是一种相对较新的免疫检查点抑制剂，于2014年获得美国食品药品监督管理局（FDA）批准，因其在治疗转移性黑色素瘤方面的疗效而得到更广泛的应用。许多已被记录的皮肤免疫相关不良事件（irAEs）并不需要停止免疫治疗，通过支持性治疗即可处理。我们报告一例因纳武单抗导致的重症多形红斑病例，该病例需要住院治疗并停止用药。这是我们所知文献中第二例报告的由纳武单抗引起的多形红斑病例，强调了肿瘤学家与皮肤科医生联合工作以进行快速诊断和管理的重要性。
